Stefan Ambs

Has grant

Senior Investigator (tenured) and Head of the Molecular Epidemiology Section

National Cancer Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Stefan Ambs is a Senior Investigator (tenured) and Head of the Molecular Epidemiology Section at the National Cancer Institute, USA. His research primarily focuses on molecular epidemiology, with recent publications examining systemic inflammation indices and their association with prostate cancer survival, the effects of chronic exposure to nitric oxide on P53 mutations, and the role of urinary PGE-M in men with prostate cancer.

Recent Grants

Grant: Close

The Molecular Profile of Prostate Tumors in African-American Men

Open Date: 2009-01-01

Close Date: 2017-01-01

Grant: Close

The Molecular Profile of Prostate Tumors in Smokers

Open Date: 2009-01-01

Close Date: 2012-01-01

Grant: Close

Non-coding RNAs as Prognostic and Diagnostic Markers in Prostate Cancer

Open Date: 2009-01-01

Close Date: 2017-01-01

Grant: Close

Novel Markers for Disease Outcome in Breast Cancer

Open Date: 2009-01-01

Close Date: 2017-01-01

Grant: Close

Maryland Prostate Cancer Case-Control Study

Open Date: 2009-01-01

Close Date: 2017-01-01

Articles (16)

S-UMAP and regional annotations identify cellular neighborhoods of interest with respect to the tumor CSC markers EpCAM and CD44v6. A, Unsupervised analysis of S-UMAP highlighting distinct EpCAM and CD44v6 expression in specific magnified regions (also shown in Fig. 5D ); red box showing CD8 − NOS2 + COX2 + phenotype in the metastatic niche (cyan) in a stroma-restricted inflamed region; yellow and blue boxes show CD8 − NOS2 − COX2 + phenotypes in immune desert regions. B, Supervised analysis showing distinct EpCAM and CD4v6 expression in regions containing tumor satellites, tumor core, NOS2 + edge, lymphoid aggregates, and NOS2 − edge.

Year:

2025

Estrogen receptor–negative breast cancer is an aggressive subtype with limited therapeutic options. Elevated nitric oxide synthase 2 (NOS2) and COX2 mediate immunosuppression and poor survival in these tumors. Therefore, the influence of tumor NOS2/COX2 on immune architecture was examined in 16 African American and five Caucasian estrogen receptor–negative tumors. Elevated tumor NOS2/COX2 limited CD8 + T-cell infiltration at 5-year survival. Distinct CD8 +/− NOS2 +/− COX2 +/− phenotypes defining metastatic and cancer stem cell niches and immune desert regions were identified. These results were supported by an unbiased, unsupervised nonlinear dimensionality reduction technique, Uniform Manifold Approximation and Projection for Dimension Reduction, incorporating spatial relations between cells and validated in a separate gene expression cohort using NOS2/CD8 and COX2/CD8 ratios. Additionally, elongated tumor cells were specifically in CD8 − NOS2 + COX2 + regions, suggesting metastatic hot spots. This work demonstrates predictive power of spatial analyses of CD8/NOS2/COX2 architecture and supports the use of clinically available NOS2/COX2 inhibitors for improved survival in patients with these aggressive tumors. Significance: This work identifies CD8 − NOS2 + COX2 + and CD8 − NOS2 − COX2 + unique cellular neighborhoods that drive the tumor immune spatial architecture of CD8 + T cells predictive of clinical outcome and can be targeted with clinically available NOS inhibitors and NSAIDs.

Year:

2025

Metastatic niche showing invasive tumor edge proximal to lymphoid aggregates. A, Composition of tumor marker CKSOX10 (blue), NOS2 (red), COX2 (green), and CD8 (magenta), in which NOS2 + and COX2 + cells (yellow circles) have migrated away from larger tumor lesion and invaded into the stroma. B, CKSOX10 tumor marker alone relative to CD8 + T-cell aggregate. C, DAPI with CD8 expression.

Year:

2024

Analysis of tumor NOS2/COX2 expression with respect to CD8 + T cells. A, Ratio of NOS2s/CD8 and COX2/CD8 expression in total and CD3 + CD8 + PD1 − cytolytic T-cell populations. B, ER − breast cancer at 5-year survival stratified for high vs. low NOS2/CD8 and COX2/CD8 ratio validation in GSE37751 breast cancer data from Genome Expression Omnibus public data repository ( https://www.ncbi.nlm.nih.gov/geo/info/download.html ). The R software (version 4.2) was used to extract gene expression data from ER − samples for analysis of high (red) vs. low (black) NOS2/CD8a and COX2/CD8a ratios dichotomized at the median. The survival data were exported to Prism (version 9) and plotted for survival. HRs and P values were determined using Mantel–Haenszel and Gehan–Breslow–Wilcoxon test in Prism software. C, Phenotype % cell distributions in each tumor sample relative to survival. Each dot represents a tumor sample, and the dashed lines denote natural breaks in the data. D, Distribution plots of NOS2s vs. CD8 + T cells of all samples showing distinct regional clustering of immune deserts, fully inflamed penetrating CD8 + T cells, and inflamed stroma-restricted CD8 + T cells in tumors from deceased (red) vs. alive (blue) patients. *, P ≤ 0.05; **, P ≤ 0.01.

Year:

2024

Defined CD8 NOS2 and COX2 spatial landscape. Five basic regions showing ( A ) margin or stroma-restricted lymphoid aggregates (orange circles) in which a gap of 50 μm (double orange arrow) between CD3 + T-cell aggregates and the CKSOX10 + tumor edge (green circle) was observed. Blue and dashed magenta circles identify immune desert regions lacking CD8 + T cells. B, Tumor fragmentation or satellite region. C, Tumor edge with proximal stroma regions. D, Significant differences in % cell composition is shown for CD8 + T cells as well as ( E ) NOS2 + and ( F ) COX2 + tumor cells. G, Graphic summary of tumor NOS2/COX2 landscape and CD8 + T-cell regional distributions with respect to the tumor–stroma interface. H, Spatial architecture of predictive phenotypes in tumors from deceased vs. alive patients. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.

Year:

2024

Spatial analysis of tumor NOS2/COX2 expression with respect to survival. Spatial landscape of NOS2 (red) and COX2 (green) with DAPI (white), the tumor marker CKSOX10 (blue) for ( A ) deceased and ( B ) alive patients at 5-year survival. C, Quantification of NOS2/COX2 tumor expression at the single cell level, with each dot representing a tumor sample (also shown in Supplementary Fig. S2). D, Heat density maps of tumor NOS2/COX2 expression in deceased and alive patient tumors. E, Significant Pearson’s correlation between tumor NOS2 and COX2 expression R 2 = 0.8481 and P F ). Mann–Whitney *, P P ≤ 0.01.

Year:

2024

S-UMAP analysis for tumor NOS2/COX2 and CD8 expression. Density heat maps show spatially distinct tumor NOS2, COX2, and CD8 clustering in tumors from ( A ) deceased and ( B ) alive patients. Spatial distribution plots based upon positive pixels for CD8 (magenta), NOS2 (red; also shown in Fig. 1D ), and COX2 (green; also shown in Fig. 1D ) expression are shown. C, Masks show distinct neighborhood cluster prevalence in deceased (red) or alive (blue) patient tumors. D, Ratio of phenotype density profiles (i.e., neighborhood cluster density profiles) in the D3/alive as well as the alive/D3 demonstrates the predictive value of CD8 − NOS2 + COX2 + (yellow diamonds) and CD8 + NOS2 − COX2 − (purple triangle) phenotypes due to their vast differences in deceased vs. alive patient tumors. E, Spatial dot plot and nearest-neighbor analysis at 50 μm distances of the defined phenotypes with a predictive value. F, mIF of CD8 (magenta) NOS2 (red) and COX2 (green) expression in areas of interest (red square boxes) in the spatial dot plot shown in E . F, (Top) entire tumor image; F , (middle) a satellite or tumor budding metastatic niche (yellow box) expressing elevated tumor NOS2; (bottom) immune desert region. G, Enhanced magnification of these areas of interest ( F , yellow and green boxes) shows a CD8 − NOS2 + COX2 + metastatic niche (top image; also shown in Fig. 1A ) and CD8 − NOS2 − COX2 + immune desert (bottom image).

Year:

2024

Spatial landscape of CD44v6 and EpCAM expression relative to tumor NOS2/COX2 expression and survival. A, Enriched regions showing spatially distinct CD44v6 and EpCAM expression. B, Quantification of CD44v6 and EpCAM as well as ratios of NOS2 or COX2 to CD44v6 or EpCAM, respectively, in tumors from deceased vs. alive patients. Significance was determined using the Mann–Whitney test, in which *, P P = 0.007. C, Lymphoid aggregate and EpCAM + tumor cell boarder. Pearson’s correlation coefficient shows significant associations between T effector cells or IFNγ and EpCAM expression in tumors from deceased vs. alive patients. D, Spatial landscape of CD44v6 and EpCAM expression in annotated tumor, lymphoid aggregate, invasive tumor/stroma, and immune desert regions. These regions show EpCAM + and CD44v6 + tumor cells that have invaded the stroma.

Year:

2024

Estrogen receptor–negative breast cancer is an aggressive subtype with limited therapeutic options. Elevated nitric oxide synthase 2 (NOS2) and COX2 mediate immunosuppression and poor survival in these tumors. Therefore, the influence of tumor NOS2/COX2 on immune architecture was examined in 16 African American and five Caucasian estrogen receptor–negative tumors. Elevated tumor NOS2/COX2 limited CD8+ T-cell infiltration at 5-year survival. Distinct CD8+/−NOS2+/−COX2+/− phenotypes defining metastatic and cancer stem cell niches and immune desert regions were identified. These results were supported by an unbiased, unsupervised nonlinear dimensionality reduction technique, Uniform Manifold Approximation and Projection for Dimension Reduction, incorporating spatial relations between cells and validated in a separate gene expression cohort using NOS2/CD8 and COX2/CD8 ratios. Additionally, elongated tumor cells were specifically in CD8−NOS2+COX2+ regions, suggesting metastatic hot spots. This work demonstrates predictive power of spatial analyses of CD8/NOS2/COX2 architecture and supports the use of clinically available NOS2/COX2 inhibitors for improved survival in patients with these aggressive tumors. Significance: This work identifies CD8−NOS2+COX2+ and CD8−NOS2−COX2+ unique cellular neighborhoods that drive the tumor immune spatial architecture of CD8+ T cells predictive of clinical outcome and can be targeted with clinically available NOS inhibitors and NSAIDs.

Year:

2024

Breast cancer includes several subtypes with distinct characteristic biological, pathologic, and clinical features. Elucidating subtype-specific genetic etiology could provide insights into the heterogeneity of breast cancer to facilitate the development of improved prevention and treatment approaches. In this study, we conducted pairwise case–case comparisons among five breast cancer subtypes by applying a case–case genome-wide association study (CC-GWAS) approach to summary statistics data of the Breast Cancer Association Consortium. The approach identified 13 statistically significant loci and eight suggestive loci, the majority of which were identified from comparisons between triple-negative breast cancer (TNBC) and luminal A breast cancer. Associations of lead variants in 12 loci remained statistically significant after accounting for previously reported breast cancer susceptibility variants, among which, two were genome-wide significant. Fine mapping implicated putative functional/causal variants and risk genes at several loci, e.g., 3q26.31/ TNFSF10 , 8q22.3/ NACAP1 / GRHL2 , and 8q23.3/ LINC00536 / TRPS1 , for TNBC as compared with luminal cancer. Functional investigation further identified rs16867605 at 8q22.3 as a SNP that modulates the enhancer activity of GRHL2 . Subtype-informative polygenic risk scores (PRS) were derived, and patients with a high subtype-informative PRS had an up to two-fold increased risk of being diagnosed with TNBC instead of luminal cancers. The CC-GWAS PRS remained statistically significant after adjusting for TNBC PRS derived from traditional case–control GWAS in The Cancer Genome Atlas and the African Ancestry Breast Cancer Genetic Consortium. The CC-GWAS PRS was also associated with overall survival and disease-specific survival among patients with breast cancer. Overall, these findings have advanced our understanding of the genetic etiology of breast cancer subtypes, particularly for TNBC. Significance: The discovery of subtype-informative genetic risk variants for breast cancer advances our understanding of the etiologic heterogeneity of breast cancer, which could accelerate the identification of targets and personalized strategies for prevention and treatment.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2021

Collaborators (34)

Sharon Glynn

Prof in Pathology

University of Galway

IRELAND
View details

Montserrat Garcia-Closas

Professor of Epidemiology

Institute of Cancer Research

UNITED KINGDOM
View details

jenny chang

Professor

Weill Cornell Medical College

UNITED STATES
View details

Christopher A. Haiman

University of Southern California

UNITED STATES
View details

Andriy Derkach

Associate Attending Biostatistician

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Christine Ambrosone

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Jennifer Hu

Professor

University of Miami

UNITED STATES
View details

Katherine Nathanson

Professor

University of Pennsylvania

UNITED STATES
View details

Xiao‐Ou Shu

Vanderbilt University Medical Center

UNITED STATES
View details

Shiv Prakash Verma

Senior Research Scientist

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Dale Sandler

Branch Chief

National Institute of Environmental Health Sciences

UNITED STATES
View details

Julie R Palmer

Boston University School of Medicine

UNITED STATES
View details

Wei Zheng

-

UNITED STATES
View details

Qiuyin Cai

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Melissa A. Troester

Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Lisa A Ridnour

Staff Scientist

National Cancer Institute

UNITED STATES
View details

GUOCHONG JIA

Vanderbilt University

UNITED STATES
View details

Andrew Olshan

University of North Carolina at Chapel Hill

UNITED STATES
View details

Jens Rittscher

Professor of Engineering Science, Senior Research Fellow

University of Oxford

UNITED KINGDOM
View details

Esther John

Professor

Stanford University School of Medicine

UNITED STATES
View details

Charles F. Lynch

-

UNITED STATES
View details

Dezheng Huo

University of Chicago

UNITED STATES
View details

Gordon Watt

Junior Group Leader

The Netherlands Cancer Institute

NETHERLANDS
View details

Xingyi Guo

Associate Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Stanley Lipkowitz

Chief

National Cancer Institute

UNITED STATES
View details

Daniel McVicar

Acting Chief

National Cancer Institute

UNITED STATES
View details

Jirong Long

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Stephen Hewitt

Editor-in-Chief

National Cancer Institute

UNITED STATES
View details

David Wink

Acting Deputy Chief

National Cancer Institute

UNITED STATES
View details

Yaohua Yang

Assistant Professor

University of Virginia

UNITED STATES
View details

Shouhui Yang

Staff Scientist

National Cancer Institute

UNITED STATES
View details

Jian Gu

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Olufunmilayo I. Olopade

Professor

University of Chicago

UNITED STATES
View details

Christopher Li

Fred Hutchinson Cancer Research Center

UNITED STATES
View details